| __timestamp | BioMarin Pharmaceutical Inc. | Ionis Pharmaceuticals, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 302156000 | 20140000 |
| Thursday, January 1, 2015 | 402271000 | 37173000 |
| Friday, January 1, 2016 | 476593000 | 48616000 |
| Sunday, January 1, 2017 | 554336000 | 108488000 |
| Monday, January 1, 2018 | 604353000 | 244622000 |
| Tuesday, January 1, 2019 | 680924000 | 287000000 |
| Wednesday, January 1, 2020 | 737669000 | 354000000 |
| Friday, January 1, 2021 | 759375000 | 186000000 |
| Saturday, January 1, 2022 | 854009000 | 151000000 |
| Sunday, January 1, 2023 | 937300000 | 232600000 |
| Monday, January 1, 2024 | 1009025000 | 267474000 |
Data in motion
In the competitive landscape of biotechnology, managing Selling, General, and Administrative (SG&A) expenses is crucial for maintaining profitability. Over the past decade, BioMarin Pharmaceutical Inc. and Ionis Pharmaceuticals, Inc. have demonstrated contrasting approaches to SG&A cost management.
BioMarin has seen a steady increase in SG&A expenses, rising from approximately $302 million in 2014 to $937 million in 2023. This represents a growth of over 200%, reflecting their aggressive expansion and investment in administrative capabilities. In contrast, Ionis Pharmaceuticals has maintained a more conservative approach, with SG&A expenses growing from $20 million in 2014 to $233 million in 2023, a more modest increase of around 1,065%.
While BioMarin's strategy may indicate a robust growth trajectory, Ionis's careful management suggests a focus on efficiency. Investors and stakeholders must weigh these strategies when considering the long-term sustainability and profitability of these biotech giants.
Novo Nordisk A/S and Ionis Pharmaceuticals, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing Pfizer Inc. and BioMarin Pharmaceutical Inc.
Comparing SG&A Expenses: BioMarin Pharmaceutical Inc. vs Opthea Limited Trends and Insights
BioMarin Pharmaceutical Inc. and Viking Therapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and ImmunityBio, Inc.
BioMarin Pharmaceutical Inc. and Iovance Biotherapeutics, Inc.: SG&A Spending Patterns Compared
SG&A Efficiency Analysis: Comparing BioMarin Pharmaceutical Inc. and Amphastar Pharmaceuticals, Inc.
Breaking Down SG&A Expenses: BioMarin Pharmaceutical Inc. vs BioCryst Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Cytokinetics, Incorporated and Ionis Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Arrowhead Pharmaceuticals, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Dynavax Technologies Corporation
Breaking Down SG&A Expenses: Ionis Pharmaceuticals, Inc. vs BioCryst Pharmaceuticals, Inc.